My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 814

    1.

    Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.

    Díaz-Delfín J, Morales M, Caelles C.

    Diabetes. 2007 Jul;56(7):1865-71. Epub 2007 Apr 6.PMID: 17416798 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.

    Li YY, Wu HS, Tang L, Feng CR, Yu JH, Li Y, Yang YS, Yang B, He QJ.

    Pharmacol Res. 2007 Oct;56(4):335-43. Epub 2007 Aug 9.PMID: 17889553 [PubMed - indexed for MEDLINE]Related articles

    3.

    Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-gamma signaling in adipocytes and myotubes.

    Kim KY, Cho HS, Jung WH, Kim SS, Cheon HG.

    Mol Pharmacol. 2007 Jun;71(6):1554-62. Epub 2007 Mar 2.PMID: 17337625 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.

    Dallaire P, Bellmann K, Laplante M, Gélinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, Prentki M, Deshaies Y, Marette A.

    Diabetes. 2008 Aug;57(8):1999-2011. Epub 2008 May 5.PMID: 18458147 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.

    Schiefelbein D, Seitz O, Goren I, Dissmann JP, Schmidt H, Bachmann M, Sader R, Geisslinger G, Pfeilschifter J, Frank S.

    Mol Pharmacol. 2008 Oct;74(4):952-63. Epub 2008 Jul 3.PMID: 18599600 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Peroxisome proliferator-activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress.

    Gardner OS, Shiau CW, Chen CS, Graves LM.

    J Biol Chem. 2005 Mar 18;280(11):10109-18. Epub 2005 Jan 13.PMID: 15649892 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor gamma (PPARgamma), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo.

    Jiang G, Dallas-Yang Q, Biswas S, Li Z, Zhang BB.

    Biochem J. 2004 Jan 15;377(Pt 2):339-46.PMID: 14556646 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

    Eur J Pharmacol. 2008 Apr 14;584(1):192-201. Epub 2008 Feb 14.PMID: 18346728 [PubMed - indexed for MEDLINE]Related articles

    9.

    Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.

    Schinner S, Krätzner R, Baun D, Dickel C, Blume R, Oetjen E.

    Br J Pharmacol. 2009 Jul;157(5):736-45. Epub 2009 Mar 26.PMID: 19338578 [PubMed - indexed for MEDLINE]Related articles

    10.

    Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.

    Arlt W, Neogi P, Gross C, Miller WL.

    J Mol Endocrinol. 2004 Apr;32(2):425-36.PMID: 15072549 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.

    Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A, Kharitonenkov A.

    J Cell Physiol. 2007 Jan;210(1):1-6.PMID: 17063460 [PubMed - indexed for MEDLINE]Related articles

    12.

    A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.

    Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, Paterniti JR Jr.

    Mol Endocrinol. 2000 Sep;14(9):1425-33.PMID: 10976920 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.

    Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, Mutoh S.

    J Pharmacol Exp Ther. 2006 Aug;318(2):863-71. Epub 2006 May 8.PMID: 16682454 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.

    Hu X, Feng Y, Liu X, Zhao XF, Yu JH, Yang YS, Sydow-Bäckman M, Hörling J, Zierath JR, Leng Y.

    Diabetologia. 2007 May;50(5):1048-57. Epub 2007 Mar 1.PMID: 17333104 [PubMed - indexed for MEDLINE]Related articles

    15.

    Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors.

    Li X, Hansen PA, Xi L, Chandraratna RA, Burant CF.

    J Biol Chem. 2005 Nov 18;280(46):38317-27. Epub 2005 Sep 22.PMID: 16179348 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.

    Albrektsen T, Frederiksen KS, Holmes WE, Boel E, Taylor K, Fleckner J.

    Diabetes. 2002 Apr;51(4):1042-51.PMID: 11916924 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.

    Li Y, Wang Z, Furukawa N, Escaron P, Weiszmann J, Lee G, Lindstrom M, Liu J, Liu X, Xu H, Plotnikova O, Prasad V, Walker N, Learned RM, Chen JL.

    J Biol Chem. 2008 Apr 4;283(14):9168-76. Epub 2008 Feb 7.PMID: 18263587 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.

    Nakano R, Kurosaki E, Yoshida S, Yokono M, Shimaya A, Maruyama T, Shibasaki M.

    Biochem Pharmacol. 2006 Jun 28;72(1):42-52. Epub 2006 Apr 7.PMID: 16696951 [PubMed - indexed for MEDLINE]Related articles

    19.

    Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.

    Kurosaki E, Nakano R, Shimaya A, Yoshida S, Ida M, Suzuki T, Shibasaki M, Shikama H.

    Biochem Pharmacol. 2003 Mar 1;65(5):795-805.PMID: 12628477 [PubMed - indexed for MEDLINE]Related articles

    20.

    Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues.

    LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, Tomas E.

    Am J Physiol Endocrinol Metab. 2006 Jul;291(1):E175-81. Epub 2006 Feb 7.PMID: 16464908 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity